Our Approach

Developing
breakthrough
products.

We have an emerging pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardio, renal and metabolic diseases.

Pipeline

Program Indication/ Condition Pre-clinical Phase 1 Phase 2 RBT-1 Veverimer CKD/metabolic acidosis Reducing the risk of post op complications in cardiothoracic surgery Stannic protoporfin/ iron sucrose Rights Phase 3 Additional programs

Pipeline

Pre-clinical Phase 1 Phase 2 RBT-1: Veverimer: Reducing the risk of post op complications in cardiothoracic surgery Undisclosed Stannic protoporfin/iron sucrose Rights Additional
programs Phase 3

Publications